EORTC Lung Cancer Group has a strong track record in initiating and conducting clinical trials across thoracic cancers. The focus is not only lung cancer but also mesothelioma and thymomas. This follows EORTC strategy to challenge, re-define and develop standards of care for loco-regional as well as for systemic treatments.
Scientific projects are designed and conducted to integrate disciplines such as imaging, translational research, quality of life and quality assurance. There are multiple partnerships, especially with national groups in Europe but also with international umbrella organisations. The group places special emphasis on recruiting and mentoring junior colleagues who are interested in pursuing an academic career in the field of thoracic oncology.
Projects testing the place of immunotherapy in the treatment of lung cancer are also ongoing such as addressing the role of immunotherapy in the adjuvant setting of lung cancer.
Related NewsAll news
Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours
Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor
PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study)
- Presented results at ESMO that showed nivolumab monotherapy demonstrates a manageable safety profile and objective activity (EORTC-ETOP NIVOTHYM 1). This is a phase II clinical trial for a rare and orphan thoracic disease in collaboration with the European Thoracic Oncology Platform (ETOP).
- Started recruitment of cohort two in NIVOTHYM 2 that could provide new treatment opportunities for rare and orphan diseases such as thymic epithelial tumors. The trial reported that immunotherapy is feasible in this population, however insufficient to meet the trial primary objective. The second cohort is currently ongoing to assess combination of nivolumab plus ipilimumab.
- Completed activation and now recruiting for a study in non-small cell lung cancer (ALKALINE) and developed a new study in small cell lung cancer (PRIMALung). Submitted a total of 10 proposals to the Board with contributions from both senior Group members and young investigators.
- The interim analysis of the PEARLS trial showed that adjuvant pembrolizumab results in a statistically significant improvement in disease-free survival versus placebo in patients with stage IB-IIIA non-small cell lung cancer regardless of the PD-L1 expression. Results will be published in 2022 in the New England Journal of Medicine.
1 Girard et al. LBA66 – Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTCETOP NIVOTHYM phase II trial. ESMO 2021 (Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/ annonc/annonc741)
EORTC has contributed to changing the standards of care for thoracic oncology:
- 1459: Exploratory analysis of the pleural mesothelioma genome by next generation sequencing
- 1495: Update of OS in 08092 and CRP marker
- 1496: Survey on Thymoma / thymic malignancy
- 1549: Pharmacogenetic analysis from the double blind randomized phase III study ofmaintenance pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung Group study
- 1557 Predict therapy in NSCLC: Studying changes in the expression of genes related to the metabolism and the chemotherapeutic activity in primary tumor and lymph and mediastinal lymph nodes infiltrated in resectable NSCLC
- 1638: Phase II, Parallel-Arm Study of MGCD265 in patients with locally advanced or metastatic NSCLC with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
IMI CANCER-ID – Cancer treatment and monitoring through identification of circulating tumor cells and tumor related nucleic acids in blood. EORTC is contributing with biological material and related data from EORTC study 1335 SPECTAlung.
European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)
Jordi Remon Masip
Institut Gustave Roussy
Institut Jules Bordet
B. Besse - Villejuif, FR
Gustave Roussy Cancer Campus
C. Faivre-Finn - Manchester, GB
Early stage NSCLC & Radiotherapy
The Christie NHS Foundation Trust
N. Girard - Paris, FR
J. Edwards - Sheffield , GB
Early stage NSCLC & Surgery
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
J. Menis - Padova, IT
Young investigator co-chair
IRCCS - Istituto Oncologico Veneto
M. Giaj Levra - Grenoble, FR
Young investigator chair
CHU de Grenoble - La Tronche - Hopital A. Michallon
L. Hendriks - Maastricht, NL
Metastatic NSCLC: systemic treatment
Academisch Ziekenhuis Maastricht
J. Von Der Thusen - Rotterdam, NL
Erasmus MC Cancer Institute, Josephine Nefkens Institute
P. Bironzo - Torino, IT
Malignant Pleural Mesothelioma
Universita Di Torino - Ospedale S. Luigi Gonzaga
D. De Ruysscher - Maastricht, NL
Metastatic NSCLC: oligometastatic disease and new developments
Maastro Clinic - Maastricht Radiation Oncology
N. Reguart - Barcelona, ES
Hospital Clinic Universitari de Barcelona
Associations of a Breast Cancer Polygenic Risk Score with Tumor Characteristics and Survival
Patient-reported outcome measures for physical function in cancer patients: content comparison of the EORTC CAT Core, EORTC QLQ-C30, SF-36, FACT-G, and PROMIS measures using the International Classification of Functioning, Disability and Health
Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033
The EORTC QLU-C10D – development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the U.K.
Relapse Patterns in early-PET negative, limited stage Hodgkin Lymphoma (HL) after ABVD with or without Radiotherapy – A joint analysis of the EORTC/FIL/LYSA H10 and NCRI RAPID Trials